Reverse Translation for Assessment of Confidence in Animal Models of Multiple Sclerosis for Drug Discovery

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical pharmacology and therapy

• Publication date

  2018-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/cpt.801PMID 28748631
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natalizumab

  2019cited by this paper
• in a Phase 2 Study

  2019cited by this paper
• Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis

  2019cited by this paper
• Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases

  2017cited by this paper
• Analysis of the cross-talk of Epstein–Barr virus-infected B cells with T cells in the marmoset

  2017cited by this paper
• Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

  2017influential reference
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

  2017cited by this paper
• EBV Infection Empowers Human B Cells for Autoimmunity: Role of Autophagy and Relevance to Multiple Sclerosis

  2017cited by this paper
• A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model

  2017cited by this paper
• Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations.

  2017cited by this paper
• Oxidative Injury and Iron Redistribution Are Pathological Hallmarks of Marmoset Experimental Autoimmune Encephalomyelitis

  2017cited by this paper
• When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data

  2017cited by this paper
• The comparative immunology of wild and laboratory mice, Mus musculus domesticus

  2017cited by this paper
• Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study

  2016cited by this paper
• EBV Infection and Multiple Sclerosis: Lessons from a Marmoset Model.

  2016cited by this paper
• Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?

  2016cited by this paper
• Lymphocryptovirus Infection of Nonhuman Primate B Cells Converts Destructive into Productive Processing of the Pathogenic CD8 T Cell Epitope in Myelin Oligodendrocyte Glycoprotein

  2016cited by this paper
• Recapitulating adult human immune traits in laboratory mice by normalizing environment

  2016cited by this paper
• Viral infection crosses up antigen presentation to drive autoimmunity

  2016cited by this paper
• The common marmoset as an indispensable animal model for immunotherapy development in multiple sclerosis.

  2016cited by this paper
• Cytomegalovirus: a culprit or protector in multiple sclerosis?

  2015cited by this paper
• The primate autoimmune encephalomyelitis model; a bridge between mouse and man

  2015cited by this paper
• Multiple sclerosis—a quiet revolution

  2015cited by this paper
• EBV and Autoimmunity.

  2015influential reference
• The Charcot Lecture | Beating MS: A story of B cells, with twists and turns

  2015cited by this paper
• Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis

  2014cited by this paper
• CD20+ B Cell Depletion Alters T Cell Homing

  2014cited by this paper
• B cell depletion alters T cell homing

  2014cited by this paper
• CNS myelin induces regulatory functions of DC-SIGN–expressing, antigen-presenting cells via cognate interaction with MOG

  2014cited by this paper
• Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

  2014cited by this paper
• Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

  2013cited by this paper
• Drainage of Cells and Soluble Antigen from the CNS to Regional Lymph Nodes

  2013cited by this paper
• Induction of Experimental Autoimmune Encephalomyelitis With Recombinant Human Myelin Oligodendrocyte Glycoprotein in Incomplete Freund’s Adjuvant in Three Non-human Primate Species

  2013influential reference
• Cytotoxic NKG2C+ CD4 T Cells Target Oligodendrocytes in Multiple Sclerosis

  2013cited by this paper
• The Different Clinical Effects of Anti-BLyS, Anti-APRIL and Anti-CD20 Antibodies Point at a Critical Pathogenic Role of γ-Herpesvirus Infected B Cells in the Marmoset EAE Model

  2013cited by this paper
• Oligodendrocytes in Multiple Sclerosis CD4 T Cells Target + Cytotoxic NKG2C

  2013cited by this paper
• The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis

  2013cited by this paper
• Will the real multiple sclerosis please stand up?

  2012cited by this paper
• Will the real multiple sclerosis please stand up?

  2012cited by this paper
• Unravelling the T‐cell‐mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG34–56 peptide in incomplete adjuvant

  2012cited by this paper
• B-Cell Depletion Abrogates T Cell–Mediated Demyelination in an Antibody-Nondependent Common Marmoset Experimental Autoimmune Encephalomyelitis Model

  2012cited by this paper
• Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys

  2012cited by this paper
• TLR-dependent T cell activation in autoimmunity

  2011cited by this paper
• EAE: imperfect but useful models of multiple sclerosis.

  2011cited by this paper
• Resident B cells regulate thymic expression of myelin oligodendrocyte glycoprotein.

  2011cited by this paper
• Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis

  2011cited by this paper
• B-Cell Depletion Attenuates White and Gray Matter Pathology in Marmoset Experimental Autoimmune Encephalomyelitis

  2011cited by this paper
• Effects of Early IL-17A Neutralization on Disease Induction in a Primate Model of Experimental Autoimmune Encephalomyelitis

  2010cited by this paper
• Induction of Progressive Demyelinating Autoimmune Encephalomyelitis in Common Marmoset Monkeys Using MOG34-56 Peptide in Incomplete Freund Adjuvant

  2010influential reference
• Are current disease‐modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?

  2010cited by this paper
• Late B Cell Depletion with a Human Anti-Human CD20 IgG1κ Monoclonal Antibody Halts the Development of Experimental Autoimmune Encephalomyelitis in Marmosets

  2010cited by this paper
• Atacicept: targeting B cells in multiple sclerosis

  2010cited by this paper
• Multiple sclerosis - a response-to-damage model.

  2009cited by this paper
• [Targeting B cells in multiple sclerosis. Current concepts and strategies].

  2009cited by this paper
• Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

  2008cited by this paper
• A prescription for human immunology.

  2008cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Transcriptional regulation by AIRE: molecular mechanisms of central tolerance

  2008cited by this paper
• Natural versus adaptive regulatory T cells.

  2005cited by this paper
• Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis

  2005cited by this paper
• Native myelin oligodendrocyte glycoprotein promotes severe chronic neurological disease and demyelination in Biozzi ABH mice

  2005cited by this paper
• Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

  2005cited by this paper
• Non-human primate models of experimental autoimmune encephalomyelitis: Variations on a theme.

  2005cited by this paper
• Suppression of Ongoing Disease in a Nonhuman Primate Model of Multiple Sclerosis by a Human-Anti-Human IL-12p40 Antibody1

  2005cited by this paper
• Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination.

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Of Mice and Not Men: Differences between Mouse and Human Immunology

  2004cited by this paper
• NK-CTLs, a novel HLA-E-restricted T-cell subset.

  2003cited by this paper
• Opinion-regulatory lymphocytes: Natural versus adaptive regulatory T cells

  2003cited by this paper
• Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP

  2002influential reference
• Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination

  2002cited by this paper
• Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using an Anti-IL-12p40 Monoclonal Antibody1

  2002cited by this paper
• Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates

  2001cited by this paper
• Myelin/Oligodendrocyte Glycoprotein-Induced Autoimmune Encephalomyelitis in Common Marmosets: The Encephalitogenic T Cell Epitope pMOG24–36 Is Presented by a Monomorphic MHC Class II Molecule1

  2000cited by this paper
• Conference Science Medal Lecture: Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration *

  1998cited by this paper
• Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus).

  1998cited by this paper
• Is EBV persistence in vivo a model for B cell homeostasis?

  1996cited by this paper
• New insights into the mechanism of action of copolymer 1 of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis

  1996cited by this paper
• New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

  1996cited by this paper
• Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate.

  1995cited by this paper
• Tolerance, danger, and the extended family.

  1994cited by this paper
• Myelin specific, autoaggressive T cell clones in the normal immune repertoire: their nature and their regulation.

  1992cited by this paper
• Molecular and cellular aspects of immunologic tolerance.

  1991cited by this paper
• Variations on a theme.

  1990cited by this paper
• Molecular genetics of the T cell-receptor beta chain.

  1985cited by this paper

• Exploiting induced pluripotent stem cell-derived retinal pigment epithelium to unravel host-pathogen interaction in ocular tuberculosis: a reverse translational in vitro model

  2025cites this paper
• Finding new analgesics: Computational pharmacology faces drug discovery challenges.

  2024cites this paper
• Multiple sclerosis and drug discovery: A work of translation

  2021cites this paper
• Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis

  2019cites this paper
• Pain pathogenesis in rheumatoid arthritis—what have we learned from animal models?

  2018cites this paper
• How Well Are We Applying Quantitative Methods to Reverse Translation to Inform Early Clinical Development?

  2018cites this paper
• Reverse Translation: The Art of Cyclical Learning

  2018cites this paper
• Patient‐Centered Reverse Translation

  2018cites this paper
• Merits and complexities of modeling multiple sclerosis in non-human primates: implications for drug discovery

  2018cites this paper
• When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data

  2017cites this paper